{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "decreases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "pubchem:9871419",
      "entity_text" : "ticagrelor",
      "entity_type" : "simple_chemical"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "uaz:UAZ01370",
      "entity_text" : "rFVIIa",
      "entity_type" : "protein"
    },
    "hypothesis_information" : false
  },
  "verbose_text" : "XREF_BIBR In conclusion, rFVIIa may decrease ticagrelor induced bleeding risk but careful assessment of the benefit-risk balance is warranted before using rFVIIa to reverse ticagrelor effects.",
  "reading_complete" : "2020-08-03T13:25:51Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-03T13:25:30Z",
  "trigger" : "decrease",
  "evidence" : [ "rFVIIa may decrease ticagrelor" ],
  "pmc_id" : "6524896",
  "score" : 0
}